Center-Authored Papers

Filters: Author is Estey, E H  [Clear All Filters]
Journal Article
Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J et al..  2017.  Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.. Leukemia. Abstract
Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee J-W, Sun Z, Tallman MS, Patel J, Gönen M et al..  2015.  Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.. Leukemia.
Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB.  2016.  Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.. Leukemia.
Estey EH.  2013.  Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.. Leukemia. 27(9):1803-12. Abstract
Estey EH.  2012.  How to manage high-risk acute myeloid leukemia.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 26(5):861-9. Abstract
Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR et al..  2015.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.. Leukemia.
Walter RB, Estey EH.  2014.  Management of older or unfit patients with acute myeloid leukemia.. Leukemia. Abstract
Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL et al..  2017.  Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.. Leukemia. Abstract
Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH et al..  2016.  PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.. Leukemia. Abstract
Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.  2016.  Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.. Leukemia. Abstract
Roshal M, Chien S, Othus M, Wood BL, Fang M, Appelbaum FR, Estey EH, Papayannopoulou T, Becker PS.  2012.  The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.
Vainstein V, Buckley SA, Shukron O, Estey EH, Abkowitz JL, Wood BL, Walter RB.  2013.  Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia.. Leukemia.
Buckley SA, Othus M, Estey EH, Walter RB.  2015.  The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy.. Blood cancer journal. 5:e276.